ARMP

The company operates using its proprietary bacteriophage-based technology. Bacteriophages are viruses that naturally infect and kill specific bacteria without harming human cells. Armata's approach is to engineer these phages into therapeutic candidates designed to target difficult-to-treat, multidrug-resistant pathogens. Its development pipeline includes product candidates such as AP-SA02 for Staphylococcus aureus bacteremia and AP-PA03 for infections caused by Pseudomonas aeruginosa. These programs aim to address serious hospital-acquired infections where traditional antibiotics are failing.

Armata Pharmaceuticals is a subsidiary of Innoviva, Inc. Its strategy centers on advancing its lead candidates through clinical trials to demonstrate safety and efficacy, with the goal of providing new treatment options in the global fight against antimicrobial resistance. The company's work targets a critical need in healthcare, particularly in hospital settings and among patients with life-threatening resistant infections. As a clinical-stage entity, its primary activities involve research, development, and collaboration within the scientific and medical communities to bring its phage-based therapies toward potential regulatory approval and commercialization.